Cargando…

The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United States

INTRODUCTION: Eosinophilic gastritis and eosinophilic enteritis (EoG/EoN) are associated with a substantial clinical burden. However, limited information is available regarding the economic burden of EoG/EoN. This study was conducted to compare healthcare resource use (HRU) and costs among patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Woolley, Michael, Cook, Erin E., Mu, Fan, Betts, Keith A., Billmyer, Emma, Yim, Erica, Chen, Jingyi, Wu, Eric Q.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309124/
https://www.ncbi.nlm.nih.gov/pubmed/35689161
http://dx.doi.org/10.1007/s12325-022-02202-5
_version_ 1784753088993689600
author Woolley, Michael
Cook, Erin E.
Mu, Fan
Betts, Keith A.
Billmyer, Emma
Yim, Erica
Chen, Jingyi
Wu, Eric Q.
author_facet Woolley, Michael
Cook, Erin E.
Mu, Fan
Betts, Keith A.
Billmyer, Emma
Yim, Erica
Chen, Jingyi
Wu, Eric Q.
author_sort Woolley, Michael
collection PubMed
description INTRODUCTION: Eosinophilic gastritis and eosinophilic enteritis (EoG/EoN) are associated with a substantial clinical burden. However, limited information is available regarding the economic burden of EoG/EoN. This study was conducted to compare healthcare resource use (HRU) and costs among patients with EoG/EoN versus without EoG/EoN in the USA. METHODS: Administrative claims data from the IBM MarketScan(®) Commercial Claims and Encounters (CCAE) and Medicare Supplemental and Coordination of Benefits Databases (2009–2019) was used to identify two cohorts of patients. Patients without EoG/EoN were matched 3:1 to patients with EoG/EoN on sex, year of birth, and healthcare plan type. Study measures included demographic characteristics, select comorbidities, all-cause HRU, and costs. Comparisons were made over a 1-year period following EoG/EoN diagnosis for patients with EoG/EoN and an eligible date for patients without EoG/EoN. RESULTS: A total of 2219 patients with EoG/EoN and 6657 patients without EoG/EoN were analyzed. Significantly higher proportions of patients with EoG/EoN versus without EoG/EoN had comorbid conditions. Rates of all-cause HRU were significantly higher among patients with EoG/EoN versus patients without EoG/EoN (adjusted rate ratio [95% confidence interval]: inpatient visits, 6.26 [5.26, 7.46]; outpatient visits, 1.17 [1.16, 1.19]; emergency department visits, 2.11 [1.98, 2.25]; all p < 0.001). Patients with EoG/EoN incurred significantly higher costs versus patients without EoG/EoN (adjusted mean cost difference $31,180; p < 0.001). Cost differences were largely due to outpatient (adjusted mean cost difference $14,018; p < 0.001) and inpatient (adjusted mean cost difference $11,224; p < 0.001) costs. CONCLUSION: The economic burden associated with EoG/EoN is substantial, with patients with EoG/EoN having a higher rate of HRU and incurring $31,180 more than patients without EoG/EoN on average. Most of the cost difference was attributable to outpatient and inpatient costs. Cost-saving strategies to lower the burden of illness in this patient population are needed.
format Online
Article
Text
id pubmed-9309124
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-93091242022-07-26 The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United States Woolley, Michael Cook, Erin E. Mu, Fan Betts, Keith A. Billmyer, Emma Yim, Erica Chen, Jingyi Wu, Eric Q. Adv Ther Original Research INTRODUCTION: Eosinophilic gastritis and eosinophilic enteritis (EoG/EoN) are associated with a substantial clinical burden. However, limited information is available regarding the economic burden of EoG/EoN. This study was conducted to compare healthcare resource use (HRU) and costs among patients with EoG/EoN versus without EoG/EoN in the USA. METHODS: Administrative claims data from the IBM MarketScan(®) Commercial Claims and Encounters (CCAE) and Medicare Supplemental and Coordination of Benefits Databases (2009–2019) was used to identify two cohorts of patients. Patients without EoG/EoN were matched 3:1 to patients with EoG/EoN on sex, year of birth, and healthcare plan type. Study measures included demographic characteristics, select comorbidities, all-cause HRU, and costs. Comparisons were made over a 1-year period following EoG/EoN diagnosis for patients with EoG/EoN and an eligible date for patients without EoG/EoN. RESULTS: A total of 2219 patients with EoG/EoN and 6657 patients without EoG/EoN were analyzed. Significantly higher proportions of patients with EoG/EoN versus without EoG/EoN had comorbid conditions. Rates of all-cause HRU were significantly higher among patients with EoG/EoN versus patients without EoG/EoN (adjusted rate ratio [95% confidence interval]: inpatient visits, 6.26 [5.26, 7.46]; outpatient visits, 1.17 [1.16, 1.19]; emergency department visits, 2.11 [1.98, 2.25]; all p < 0.001). Patients with EoG/EoN incurred significantly higher costs versus patients without EoG/EoN (adjusted mean cost difference $31,180; p < 0.001). Cost differences were largely due to outpatient (adjusted mean cost difference $14,018; p < 0.001) and inpatient (adjusted mean cost difference $11,224; p < 0.001) costs. CONCLUSION: The economic burden associated with EoG/EoN is substantial, with patients with EoG/EoN having a higher rate of HRU and incurring $31,180 more than patients without EoG/EoN on average. Most of the cost difference was attributable to outpatient and inpatient costs. Cost-saving strategies to lower the burden of illness in this patient population are needed. Springer Healthcare 2022-06-10 2022 /pmc/articles/PMC9309124/ /pubmed/35689161 http://dx.doi.org/10.1007/s12325-022-02202-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Woolley, Michael
Cook, Erin E.
Mu, Fan
Betts, Keith A.
Billmyer, Emma
Yim, Erica
Chen, Jingyi
Wu, Eric Q.
The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United States
title The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United States
title_full The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United States
title_fullStr The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United States
title_full_unstemmed The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United States
title_short The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United States
title_sort economic burden of eosinophilic gastritis and eosinophilic enteritis in the united states
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309124/
https://www.ncbi.nlm.nih.gov/pubmed/35689161
http://dx.doi.org/10.1007/s12325-022-02202-5
work_keys_str_mv AT woolleymichael theeconomicburdenofeosinophilicgastritisandeosinophilicenteritisintheunitedstates
AT cookerine theeconomicburdenofeosinophilicgastritisandeosinophilicenteritisintheunitedstates
AT mufan theeconomicburdenofeosinophilicgastritisandeosinophilicenteritisintheunitedstates
AT bettskeitha theeconomicburdenofeosinophilicgastritisandeosinophilicenteritisintheunitedstates
AT billmyeremma theeconomicburdenofeosinophilicgastritisandeosinophilicenteritisintheunitedstates
AT yimerica theeconomicburdenofeosinophilicgastritisandeosinophilicenteritisintheunitedstates
AT chenjingyi theeconomicburdenofeosinophilicgastritisandeosinophilicenteritisintheunitedstates
AT wuericq theeconomicburdenofeosinophilicgastritisandeosinophilicenteritisintheunitedstates
AT woolleymichael economicburdenofeosinophilicgastritisandeosinophilicenteritisintheunitedstates
AT cookerine economicburdenofeosinophilicgastritisandeosinophilicenteritisintheunitedstates
AT mufan economicburdenofeosinophilicgastritisandeosinophilicenteritisintheunitedstates
AT bettskeitha economicburdenofeosinophilicgastritisandeosinophilicenteritisintheunitedstates
AT billmyeremma economicburdenofeosinophilicgastritisandeosinophilicenteritisintheunitedstates
AT yimerica economicburdenofeosinophilicgastritisandeosinophilicenteritisintheunitedstates
AT chenjingyi economicburdenofeosinophilicgastritisandeosinophilicenteritisintheunitedstates
AT wuericq economicburdenofeosinophilicgastritisandeosinophilicenteritisintheunitedstates